Showing results (561-570 of 1,087) with videos related to

Sort By:
Pageof 109
European Heart Journal. Cardiovascular Pharmacotherapy|November 25, 2023
Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: the TAPER-S randomized studyDomenico D'Amario, Mattia Galli, Attilio Restivo, et al.
JACC. Cardiovascular Interventions|August 23, 2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) StudyFrancesco Franchi, Fabiana Rollini, Luis Ortega-Paz, et al.
Thrombosis and Haemostasis|January 4, 2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic DiseaseMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Lancet (London, England)|September 3, 2025
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysisMarco Valgimigli, Ki Hong Choi, Daniele Giacoppo, et al.
JAMA|January 19, 2012
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trialDominick J Angiolillo, Michael S Firstenberg, Matthew J Price, et al.
Blood Advances|March 29, 2018
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarctionOliver Borst, Patrick Münzer, Nada Alnaggar, et al.
American Heart Journal|December 5, 2016
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT studyUsman Baber, George Dangas, David J Cohen, et al.
Annals of Internal Medicine|July 21, 2020
Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized TrialMaurizio Menichelli, Franz-Josef Neumann, Gjin Ndrepepa, et al.
Circulation|February 8, 2021
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 UpdateDominick J Angiolillo, Deepak L Bhatt, Christopher P Cannon, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 30, 2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapyMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Pageof 109